-
1
-
-
33646870784
-
Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer
-
Booton R, Ward T, Heighway J, Taylor P, Power F, Ashcroft L, Morris J, Thatcher N (2006) Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 106: 2421-2427
-
(2006)
Cancer
, vol.106
, pp. 2421-2427
-
-
Booton, R.1
Ward, T.2
Heighway, J.3
Taylor, P.4
Power, F.5
Ashcroft, L.6
Morris, J.7
Thatcher, N.8
-
2
-
-
0037426052
-
Problems of reporting genetic associations with complex outcomes
-
Colhoun HM, McKeigue PM, Davey SG (2003) Problems of reporting genetic associations with complex outcomes. Lancet 361: 865-872
-
(2003)
Lancet
, vol.361
, pp. 865-872
-
-
Colhoun, H.M.1
McKeigue, P.M.2
Davey, S.G.3
-
3
-
-
33748754078
-
The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment
-
Colton SL, Xu XS, Wang YA, Wang G (2006) The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment. J Biol Chem 281: 27117-27125
-
(2006)
J Biol Chem
, vol.281
, pp. 27117-27125
-
-
Colton, S.L.1
Xu, X.S.2
Wang, Y.A.3
Wang, G.4
-
5
-
-
34249812370
-
Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer
-
Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, Gregori D, DeMarchi M, Scagliotti GV (2007) Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 13: 2876-2881
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2876-2881
-
-
Giachino, D.F.1
Ghio, P.2
Regazzoni, S.3
Mandrile, G.4
Novello, S.5
Selvaggi, G.6
Gregori, D.7
DeMarchi, M.8
Scagliotti, G.V.9
-
6
-
-
4344567395
-
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy
-
Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22: 2594-2601
-
(2004)
J Clin Oncol
, vol.22
, pp. 2594-2601
-
-
Gurubhagavatula, S.1
Liu, G.2
Park, S.3
Zhou, W.4
Su, L.5
Wain, J.C.6
Lynch, T.J.7
Neuberg, D.S.8
Christiani, D.C.9
-
7
-
-
54949085398
-
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
-
Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765
-
(2008)
N Engl J Med
, vol.359
, pp. 1757-1765
-
-
Karapetis, C.S.1
Khambata-Ford, S.2
Jonker, D.J.3
O'Callaghan, C.J.4
Tu, D.5
Tebbutt, N.C.6
Simes, R.J.7
Chalchal, H.8
Shapiro, J.D.9
Robitaille, S.10
Price, T.J.11
Shepherd, L.12
Au, H.J.13
Langer, C.14
Moore, M.J.15
Zalcberg, J.R.16
-
8
-
-
34548726841
-
Silent SNPs: Impact on gene function and phenotype
-
Komar AA (2007) Silent SNPs: impact on gene function and phenotype. Pharmacogenomics 8: 1075-1080
-
(2007)
Pharmacogenomics
, vol.8
, pp. 1075-1080
-
-
Komar, A.A.1
-
9
-
-
33749598266
-
Randomised study of sequential vs combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study
-
Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Akkermans-Vogelaar JM, Punt CJ (2006) Randomised study of sequential vs combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. Ann Oncol 17: 1523-1528
-
(2006)
Ann Oncol
, vol.17
, pp. 1523-1528
-
-
Koopman, M.1
Antonini, N.F.2
Douma, J.3
Wals, J.4
Honkoop, A.H.5
Erdkamp, F.L.6
de Jong, R.S.7
Rodenburg, C.J.8
Vreugdenhil, G.9
Akkermans-Vogelaar, J.M.10
Punt, C.J.11
-
10
-
-
34447277453
-
Sequential vs combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial
-
Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van BA, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ (2007) Sequential vs combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370: 135-142
-
(2007)
Lancet
, vol.370
, pp. 135-142
-
-
Koopman, M.1
Antonini, N.F.2
Douma, J.3
Wals, J.4
Honkoop, A.H.5
Erdkamp, F.L.6
de Jong, R.S.7
Rodenburg, C.J.8
Vreugdenhil, G.9
Loosveld, O.J.10
van, B.A.11
Sinnige, H.A.12
Creemers, G.J.13
Tesselaar, M.E.14
Slee, P.H.15
Werter, M.J.16
Mol, L.17
Dalesio, O.18
Punt, C.J.19
-
11
-
-
17444422174
-
Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy
-
Kweekel DM, Gelderblom H, Guchelaar HJ (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31: 90-105
-
(2005)
Cancer Treat Rev
, vol.31
, pp. 90-105
-
-
Kweekel, D.M.1
Gelderblom, H.2
Guchelaar, H.J.3
-
12
-
-
48249145381
-
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: A Dutch Colorectal Cancer Group study
-
Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJ, Guchelaar HJ (2008) UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer 99: 275-282
-
(2008)
Br J Cancer
, vol.99
, pp. 275-282
-
-
Kweekel, D.M.1
Gelderblom, H.2
Van der Straaten, T.3
Antonini, N.F.4
Punt, C.J.5
Guchelaar, H.J.6
-
13
-
-
37649009185
-
Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: Relationships with treatment outcome
-
Le Morvan V, Smith D, Laurand A, Brouste V, Bellott R, Soubeyran I, Mathoulin-Pelissier S, Robert J (2007) Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8: 1693-1703
-
(2007)
Pharmacogenomics
, vol.8
, pp. 1693-1703
-
-
Le Morvan, V.1
Smith, D.2
Laurand, A.3
Brouste, V.4
Bellott, R.5
Soubeyran, I.6
Mathoulin-Pelissier, S.7
Robert, J.8
-
14
-
-
33645814832
-
Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer
-
Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, Abbruzzese JL (2006) Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 24: 1720-1728
-
(2006)
J Clin Oncol
, vol.24
, pp. 1720-1728
-
-
Li, D.1
Frazier, M.2
Evans, D.B.3
Hess, K.R.4
Crane, C.H.5
Jiao, L.6
Abbruzzese, J.L.7
-
15
-
-
39049168449
-
Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/ fluoropyrimidine
-
Monzo M, Moreno I, Navarro A, Ibeas R, Artells R, Gel B, Martinez F, Moreno J, Hernandez R, Navarro-Vigo M (2007) Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/ fluoropyrimidine. Oncology 72: 364-370
-
(2007)
Oncology
, vol.72
, pp. 364-370
-
-
Monzo, M.1
Moreno, I.2
Navarro, A.3
Ibeas, R.4
Artells, R.5
Gel, B.6
Martinez, F.7
Moreno, J.8
Hernandez, R.9
Navarro-Vigo, M.10
-
16
-
-
42249105871
-
Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer
-
Okazaki T, Jiao L, Chang P, Evans DB, Abbruzzese JL, Li D (2008) Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. Clin Cancer Res 14: 2042-2048
-
(2008)
Clin Cancer Res
, vol.14
, pp. 2042-2048
-
-
Okazaki, T.1
Jiao, L.2
Chang, P.3
Evans, D.B.4
Abbruzzese, J.L.5
Li, D.6
-
17
-
-
0035893755
-
A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer
-
Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61: 8654-8658
-
(2001)
Cancer Res
, vol.61
, pp. 8654-8658
-
-
Park, D.J.1
Stoehlmacher, J.2
Zhang, W.3
Tsao-Wei, D.D.4
Groshen, S.5
Lenz, H.J.6
-
18
-
-
4143107582
-
ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy
-
Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ (2003) ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1: 162-166
-
(2003)
Clin Adv Hematol Oncol
, vol.1
, pp. 162-166
-
-
Park, D.J.1
Zhang, W.2
Stoehlmacher, J.3
Tsao-Wei, D.4
Groshen, S.5
Gil, J.6
Yun, J.7
Sones, E.8
Mallik, N.9
Lenz, H.J.10
-
19
-
-
6944234851
-
New options and old dilemmas in the treatment of patients with advanced colorectal cancer
-
Punt CJ (2004) New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 15: 1453-1459
-
(2004)
Ann Oncol
, vol.15
, pp. 1453-1459
-
-
Punt, C.J.1
-
20
-
-
34247105821
-
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
-
Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25: 1247-1254
-
(2007)
J Clin Oncol
, vol.25
, pp. 1247-1254
-
-
Ruzzo, A.1
Graziano, F.2
Loupakis, F.3
Rulli, E.4
Canestrari, E.5
Santini, D.6
Catalano, V.7
Ficarelli, R.8
Maltese, P.9
Bisonni, R.10
Masi, G.11
Schiavon, G.12
Giordani, P.13
Giustini, L.14
Falcone, A.15
Tonini, G.16
Silva, R.17
Mattioli, R.18
Floriani, I.19
Magnani, M.20
more..
-
21
-
-
34748848707
-
Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients
-
Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, Follen M, Wu X (2007) Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 107: S223-S229
-
(2007)
Gynecol Oncol
, vol.107
-
-
Saldivar, J.S.1
Lu, K.H.2
Liang, D.3
Gu, J.4
Huang, M.5
Vlastos, A.T.6
Follen, M.7
Wu, X.8
-
22
-
-
44749094927
-
Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer
-
Schrauder M, Frank S, Strissel PL, Lux MP, Bani MR, Rauh C, Sieber CC, Heusinger K, Hartmann A, Schulz-Wendtland R, Strick R, Beckmann MW, Fasching PA (2008) Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. J Cancer Res Clin Oncol 134: 873-882
-
(2008)
J Cancer Res Clin Oncol
, vol.134
, pp. 873-882
-
-
Schrauder, M.1
Frank, S.2
Strissel, P.L.3
Lux, M.P.4
Bani, M.R.5
Rauh, C.6
Sieber, C.C.7
Heusinger, K.8
Hartmann, A.9
Schulz-Wendtland, R.10
Strick, R.11
Beckmann, M.W.12
Fasching, P.A.13
-
23
-
-
3843130823
-
A multivariate analysis of genomic polymorphisms: Prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
-
Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91: 344-354
-
(2004)
Br J Cancer
, vol.91
, pp. 344-354
-
-
Stoehlmacher, J.1
Park, D.J.2
Zhang, W.3
Yang, D.4
Groshen, S.5
Zahedy, S.6
Lenz, H.J.7
-
24
-
-
34247172071
-
Genetic polymorphisms and treatment response in advanced non-small cell lung cancer
-
Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y, Deng Q, Smith S, Yu H (2007) Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 56: 281-288
-
(2007)
Lung Cancer
, vol.56
, pp. 281-288
-
-
Su, D.1
Ma, S.2
Liu, P.3
Jiang, Z.4
Lv, W.5
Zhang, Y.6
Deng, Q.7
Smith, S.8
Yu, H.9
-
25
-
-
20044368468
-
Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients
-
Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, Wain JC, Neuberg D, Liu G, Christiani DC (2005) Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 11: 1534-1538
-
(2005)
Clin Cancer Res
, vol.11
, pp. 1534-1538
-
-
Suk, R.1
Gurubhagavatula, S.2
Park, S.3
Zhou, W.4
Su, L.5
Lynch, T.J.6
Wain, J.C.7
Neuberg, D.8
Liu, G.9
Christiani, D.C.10
-
26
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van, G.M.8
van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
27
-
-
0035503151
-
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
-
Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106
-
(2001)
J Clin Oncol
, vol.19
, pp. 4097-4106
-
-
Van Cutsem, E.1
Twelves, C.2
Cassidy, J.3
Allman, D.4
Bajetta, E.5
Boyer, M.6
Bugat, R.7
Findlay, M.8
Frings, S.9
Jahn, M.10
McKendrick, J.11
Osterwalder, B.12
Perez-Manga, G.13
Rosso, R.14
Rougier, P.15
Schmiegel, W.H.16
Seitz, J.F.17
Thompson, P.18
Vieitez, J.M.19
Weitzel, C.20
Harper, P.21
more..
-
28
-
-
33748601578
-
Multiplex pyrosequencing of two polymorphisms in DNA repair gene XRCC1
-
Van der Straaten T, Kweekel D, Tiller M, Bogaartz J, Guchelaar HJ (2006) Multiplex pyrosequencing of two polymorphisms in DNA repair gene XRCC1. J Mol Diagn 8: 444-448
-
(2006)
J Mol Diagn
, vol.8
, pp. 444-448
-
-
Van der Straaten, T.1
Kweekel, D.2
Tiller, M.3
Bogaartz, J.4
Guchelaar, H.J.5
-
29
-
-
24344479165
-
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer
-
Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F (2005) ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11: 6212-6217
-
(2005)
Clin Cancer Res
, vol.11
, pp. 6212-6217
-
-
Viguier, J.1
Boige, V.2
Miquel, C.3
Pocard, M.4
Giraudeau, B.5
Sabourin, J.C.6
Ducreux, M.7
Sarasin, A.8
Praz, F.9
-
30
-
-
36249029788
-
Pathway-based approaches for analysis of genomewide association studies
-
Wang K, Li M, Bucan M (2007) Pathway-based approaches for analysis of genomewide association studies. Am J Hum Genet 81: 1278-1283
-
(2007)
Am J Hum Genet
, vol.81
, pp. 1278-1283
-
-
Wang, K.1
Li, M.2
Bucan, M.3
-
31
-
-
4143051317
-
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
-
Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC (2004) Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10: 4939-4943
-
(2004)
Clin Cancer Res
, vol.10
, pp. 4939-4943
-
-
Zhou, W.1
Gurubhagavatula, S.2
Liu, G.3
Park, S.4
Neuberg, D.S.5
Wain, J.C.6
Lynch, T.J.7
Su, L.8
Christiani, D.C.9
|